Clinical trials: RCC, open to volunteers
Renal Tumor, Renal Cell Carcinoma
PET/MR for Characterization of Renal Masses (RMs)
The frequency of kidney tumors found incidentally on imaging studies performed for unrelated reasons continues to increase leading to more surgeries and ablations for the treatment of renal masses thought to be cancer.
- Conditions
- Renal Tumor, Renal Cell Carcinoma, Renal Tumor, Benign
- Trial name
- NCT06076538
- Testing
- 2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging
- Where
- 2 sites in United States
- Volunteers
- 97 people
- Sponsor
- University of Texas Southwestern Medical Center
Clear Cell Renal Cell Carcinoma
A Study of CA9-Targeted CAR Macrophage Therapy in Advanced Clear Cell Renal Cell Carcinoma
Clear cell renal cell carcinoma is the most common type of kidney cancer. Although new treatments such as immune checkpoint inhibitors and targeted therapies have improved outcomes for many patients, some patients with advanced…
- Trial name
- CM-BA-9 (NCT07865832)
- Testing
- CM-BA-9
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Liangyou Gu
Papillary Renal Carcinoma, Variant Histology Urothelial Carcinoma
Genitourinary Tumors With Sacituzumab Tirumotecan
RINGQUEST is a Phase 2, open-label, single arm, basket, investigator-initiated clinical trial of sacituzumab tirumotecan in patients with: Cohort 1: papillary renal carcinoma (pRCC).
- Trial name
- RINGQUEST (NCT07716917)
- Testing
- Sacituzumab Tirumotecan (SKB264)
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Cancer, Renal Cell Carcinoma (RCC)
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to…
- Conditions
- Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET)
- Trial name
- NCT07620574
- Testing
- Cabozantinib, Zanzalintinib, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Exelixis
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
- Conditions
- Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- ELEPHAS-04 (NCT06349642)
- Testing
- Biospecimen Collection, Tissue Collection
- Where
- 3 sites in United States
- Volunteers
- 324 people
- Sponsor
- Mayo Clinic
Kidney Cancer
Protocol Active Surveillance Small Renal Masses (SRMs)
Prospective study of active surveillance, non-randomized, multicentric, in asymptomatic patients over the age of 50 years, not affected by other tumors, with occasional diagnosis of single monolateral solid renal mass equal to or…
- Trial name
- NCT03804320
- Testing
- Active Surveillance
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- IRCCS San Raffaele
Renal Cell Carcinoma (RCC)
Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk Recurrent Renal Carcinoma
This is a prospective cohort study aimed at clarifying the predictive value of MRD for postoperative DFS and OS in high-risk recurrent renal cell carcinoma patients who have undergone radical nephrectomy and received adjuvant…
- Trial name
- NCT07657325
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Tianjin Medical University Second Hospital
Kidney Neoplasm
Clinical Trial Addressing the Best Surgical Approach for Partial Nephrectomy With Single Port Robotic System in the Management of Localized Renal Cell Carcinoma
This study aims to find out which surgical position is safer and works better for patients candidate to robot-assisted partial nephrectomy (RAPN) - a minimally invasive procedure to remove a small kidney tumor while preserving…
- Trial name
- K3 (NCT07234409)
- Testing
- STANDARD FLANK APPROACH, Supine anterior retroperitoneal approach (SARA).
- Where
- Italy
- Volunteers
- 124 people
- Sponsor
- Niguarda Hospital
Liver Cancer (Primary and Metastatic), Renal Cancer
Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology
This is a pilot study to evaluate the feasibility, image quality, and procedural utility of a novel spectral CT technique using Canon Medical's 4D CT system during image-guided interventional oncology procedures
- Trial name
- NCT07303725
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Palo Alto Veterans Institute for Research
Renal Cell Carcinoma
Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC)
This is a non-randomized, open-label phase II study designed to estimate 12-month treatment-free survival rate following total consolidative metastasis-and-primary directed therapy (MPDT) among patients with partial…
- Trial name
- NCT06770855
- Testing
- Total consolidative MPDT
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Collecting Duct Carcinoma
Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma
This is a phase II trial to evaluate the efficacy and safety of immune checkpoint inhibitors in combination with axitinib for previously treated advanced collecting duct carcinoma.
- Trial name
- NCT06211114
- Testing
- PD-(L)1 inhibitor, Axitinib
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Kidney Cancer
Renal Cancer Detection Using Convolutional Neural Networks
We aim to experiment and implement various deep learning architectures in order to achieve human-level accuracy in Computer-aided diagnosis (CAD) systems.
- Trial name
- RCCCNN (NCT03857373)
- Where
- Denmark
- Volunteers
- 5,000 people
- Sponsor
- Nessn Azawi
Metastatic Kidney Cancer, Metastatic Kidney Carcinoma
CARE1 Pragmatic Clinical Trial
Systemic therapy for renal cell carcinoma (RCC) relies on 2 classes of agents: anti-angiogenic targeted therapy (Vascular endothelial growth factor Tyrosine Kinase Inhibitor- VEGFR TKI) and immune checkpoint inhibitor (ICI)…
- Trial name
- CARE1 (NCT06364631)
- Testing
- Nivolumab, Ipilimumab, Pembrolizumab
- Where
- 46 sites in Austria, Czechia and 2 more
- Volunteers
- 1,250 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Renal Cancer, Kidney Cancer
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
The primary objective of this study is to evaluate whether the combination of Pembrolizumab and Axitinib given in the neoadjuvant setting can change the Inferior Vena Cava Tumor Thrombus burden.
- Conditions
- Renal Cancer, Kidney Cancer, Renal Cell Carcinoma, Inferior Vena Cava Thrombosis
- Trial name
- NEOPAX (NCT05969496)
- Testing
- Axitinib, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of Colorado, Denver
Advanced Renal Cell Carcinoma (RCC)
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with other agents in participants with advanced Renal Cell Carcinoma (RCC)
- Trial name
- NCT07293351
- Testing
- Pumitamig, Ipilimumab, Cabozantinib
- Where
- 95 sites in United States, Argentina and 18 more
- Volunteers
- 474 people
- Sponsor
- Bristol-Myers Squibb
Von Hippel Lindau, Von Hippel Lindau Disease
Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial
The BELIEVE-VHL Trial is a prospective real-life study designed to evaluate the therapeutic effects, benefits, and adverse effects of belzutifan, as well as the timing of treatment response and disease progression in patients…
- Conditions
- Von Hippel Lindau, Von Hippel Lindau Disease, Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma, Hemangioblastoma (HB) of the Central Nervous System (CNS)
- Trial name
- BELIEVE-VHL (NCT07167329)
- Testing
- Belzutifan
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- José Claudio Casali da Rocha
Renal Cancer
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
This Phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 in combination with tyrosine kinase inhibitor (TKI) with or without pembrolizumab (BL-B01D1+TKI±Pembrolizumab) in patients with locally…
- Trial name
- NCT06962787
- Testing
- BL-B01D1, Axitinib, Lenvatinib
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
RCC, Renal Cell Cancer
A Study Evaluating the Value of 68Ga-NOTA-RCCB6 PET Imaging for Targeting CD70 in the Clinical Staging, Therapeutic Evaluation, and Restaging of Renal Cell Carcinoma, and Comparing It with 68Ga-PSMA PET/CT Imaging
This is a prospective, open-label, single-center clinical study targeting renal cell carcinoma. Sixty patients with a high clinical suspicion of renal cell carcinoma were included.
- Trial name
- NCT06769893
- Testing
- 68Ga-NOTA-RCCB6 PET/CT Scan
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xijing Hospital
Renal Cell Carcinoma (RCC)
Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC
This is a phase II study to determine the efficacy and safety of Super-selective tumor artery embolization combined with toripalimab and axitinib as treatment for patients with the advanced kidney cancer .
- Trial name
- NCT07172386
- Testing
- Toripalimab and axitinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Second Hospital
Kidney Cancers, Prostate Cancer
Assessment of Intelligent Algorithms for Detection, Diagnosis and Risk Stratification of Tumors of the Kidney and Prostate
The COMFORT study will evaluate an artificial intelligence-based platform developed to support the clinical assessment of kidney and prostate cancer.
- Trial name
- COMFORT (NCT07888322)
- Testing
- Medical Reading, AI assisted Medical reading
- Where
- 6 sites in Germany, Greece and 2 more
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Aristotle University Of Thessaloniki